| Gene symbol | CD19 | Synonyms | B4, CVID3 | Type of gene | protein-coding |
| Chromosome | 16 | Map location | 16p11.2 | dbXrefs | |
| Description | CD19 molecule | ||||
| GTO ID | GTC0517 |
| Trial ID | NCT04257578 |
| Disease | Primary Mediastinal B-Cell Lymphoma | Diffuse Large B-Cell Lymphoma | Follicular Lymphoma | Diffuse Large B-Cell Lymphoma Activated B-Cell Type | B-Cell Non-Hodgkin's Lymphoma | High-Grade B-Cell Lymphoma |
| Altered gene | CD19 |
| Therapeutic/Target gene | Target gene |
| Therapy | CAR-T cell |
| Treatment | YesCAR-Ta|Axicabtagene Ciloleucel|axi-cel |
| Co-treatment | acalabrutinib |
| Generation | 2nd |
| Phase | Phase1|Phase2 |
| Recruitment status | Recruiting |
| Title | Acalabrutinib and Anti-CD19 CAR T-cell Therapy for the Treatment of B-cell Lymphoma |
| Year | 2020 |
| Country | United States |
| Company sponsor | University of Washington |
| Other ID(s) | RG1006269|NCI-2020-00238|10418 |
| Vector information | |||||
|
|||||
| Cohort 1 | |||||||||||||||||
|
|||||||||||||||||